Your Article Summary
See Latest ArticlesAmgen Exercises Option for Exclusive License to Cytokinetics Cardiac Contractility Program That Includes CK-1827452
Amgen, 05/27/09
Cytokinetics Incorporated and Amgen Inc. announced that Amgen has exercised its option to obtain an exclusive license, worldwide, to Cytokinetics' cardiac contractility program. The license includes CK-1827452, a novel cardiac myosin activator being developed for the treatment of heart failure.
Today in Licensure/Accreditation...keeping you current
Receive free subspecialty "5-minute updates" via email
EDI Accrediting Firm Updates Criteria
HealthDataManagement, 12/09/09
Consumer Demand for H1N1 Information Highlights Importance of Accreditation for Health Call Centers
URAC News Releases, 12/07/09
The Joint Commission’s Hospital Accreditation Recognized by CMS
Joint Commission news, 12/03/09